WO2011049625A1 - Method for aflatoxin screening of products - Google Patents
Method for aflatoxin screening of products Download PDFInfo
- Publication number
- WO2011049625A1 WO2011049625A1 PCT/US2010/002804 US2010002804W WO2011049625A1 WO 2011049625 A1 WO2011049625 A1 WO 2011049625A1 US 2010002804 W US2010002804 W US 2010002804W WO 2011049625 A1 WO2011049625 A1 WO 2011049625A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aflatoxin
- composite
- bins
- sample
- bin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56961—Plant cells or fungi
Definitions
- the present invention relates to a method for avoiding waste of food and other products related to a positive test for the presence of aflatoxin and similar toxins.
- microbial toxins such as aflatoxin and other mycotoxins
- pistachio and almond aflatoxin testing relies on collecting 5-10 kg of sample from 20-22 bins/bags of products, each containing about 2000 pounds of the product. The sample is then homogenized/blended and a small portion (150 grams) is subjected to ethanol extraction followed by cleanup and detection. Under the prior art, if the sample tests positive, all 20-22 bins/bags are typically destroyed, with economic loss to the producers.
- each bin/bag is sampled individually, each sample is
- a new composite is formed from bags/bins that have below acceptable limit levels of the toxin, and tested to issue a certificate of analysis.
- bags that have a mean average of toxin level falling below the acceptable limit for the lot can be used to form a composite and an additional test performed to verify the level of toxin in this composite.
- the final composite may not need to be formed and tested. Instead an arithmetic mean of the bags that have suitable levels of toxins can be calculated to estimate a final level and issue a certificate based on individual bag/bin/test results.
- aflatoxin is used as an exemplary toxin which may be deal with using the disclosed process.
- the process may just as well be used with other mycotoxins or other forms of contamination as needs dictate.
- Fig. 1 is a flow diagram of the method disclosed herein.
- Fig. 1 shows test lot 1, which is a collection of bins 2 containing product 3, which may be food product such as nuts, including pistachios or almonds.
- Sampling device 4 is used to take a sample of product from each bin, each sample is homogenized by blending device 5, and placed in individual sample containers 6. A portion of the contents of each container 6 is then taken and placed in composite sample container 7. The contents of 7 are well mixed and subjected to aflatoxin testing process 8. Meanwhile, each container 6 and its remaining contents are stored in holding area 9. If the results of testing process 8 show aflatoxin at acceptable levels, then the entire test lot of bins is released for delivery to the customer.
- results of testing process 8 show aflatoxin above acceptable limits in the test lot, then individual containers in holding area 9, each containing sample from a single bin 2, are tested to determine the level of aflatoxin present in individual bins 2. If a particular bin 2 is thus identified to have an above-acceptable level of aflatoxin, that bin is excluded from shipment.
- the remaining bins may be assembled into a lot that may be released to the customer, and a certificate of compliance with aflatoxin standards for the lot may be based upon the mathematically averaged results of the previous individual tests or upon additional testing of a composite formed from taking samples from such of the individual samples 6 as tested at acceptable levels.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27955709P | 2009-10-20 | 2009-10-20 | |
| US61/279,557 | 2009-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011049625A1 true WO2011049625A1 (en) | 2011-04-28 |
Family
ID=43900599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2010/002804 Ceased WO2011049625A1 (en) | 2009-10-20 | 2010-10-19 | Method for aflatoxin screening of products |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011049625A1 (en) |
Citations (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| US3969287A (en) | 1972-12-08 | 1976-07-13 | Boehringer Mannheim Gmbh | Carrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding group and reacting the product with a carrier |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4247642A (en) | 1977-02-17 | 1981-01-27 | Sumitomo Chemical Company, Limited | Enzyme immobilization with pullulan gel |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US4301144A (en) | 1979-07-11 | 1981-11-17 | Ajinomoto Company, Incorporated | Blood substitute containing modified hemoglobin |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4670417A (en) | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| WO1990005719A1 (en) | 1988-11-23 | 1990-05-31 | British Bio-Technology Limited | Hydroxamic acid based collagenase inhibitors |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| WO1993021259A1 (en) | 1992-04-14 | 1993-10-28 | Cornell Research Foundation Inc. | Dendritic based macromolecules and method of production |
| EP0606046A1 (en) | 1993-01-06 | 1994-07-13 | Ciba-Geigy Ag | Arylsulfonamido-substituted hydroxamic acids |
| JPH08175990A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | PI3 kinase inhibitor and method for producing the same |
| JPH08176070A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Didepside derivative and PI3 kinase inhibitor |
| WO1996027583A1 (en) | 1995-03-08 | 1996-09-12 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| WO1996033172A1 (en) | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
| WO1997015658A1 (en) | 1995-10-26 | 1997-05-01 | Ludwig Institute For Cancer Research | Wortmannin phosphoinositide 3-kinase interaction site |
| EP0780386A1 (en) | 1995-12-20 | 1997-06-25 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
| WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| WO1998007697A1 (en) | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| WO1998033768A1 (en) | 1997-02-03 | 1998-08-06 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| WO1998034918A1 (en) | 1997-02-11 | 1998-08-13 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| WO1998034915A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| WO1999002514A2 (en) | 1997-07-08 | 1999-01-21 | Bristol-Myers Squibb Company | Epothilone derivatives |
| WO1999029667A1 (en) | 1997-12-05 | 1999-06-17 | Pfizer Limited | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors |
| EP0931788A2 (en) | 1998-01-27 | 1999-07-28 | Pfizer Limited | Metalloprotease inhibitors |
| WO1999052910A1 (en) | 1998-04-10 | 1999-10-21 | Pfizer Products Inc. | Bicyclic hydroxamic acid derivatives |
| WO1999052889A1 (en) | 1998-04-10 | 1999-10-21 | Pfizer Products Inc. | (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
| JP2001247477A (en) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | Antitumor agent |
| WO2001081346A2 (en) | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| WO2003034997A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| WO2003035618A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| WO2003037886A2 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| US6608056B1 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd | Fused heteroaryl derivatives |
| WO2004006916A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility |
| WO2004007491A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
| US20040053946A1 (en) | 2001-01-16 | 2004-03-18 | Lackey Karen Elizabeth | Cancer treatment method |
| EP1417976A1 (en) | 2001-07-26 | 2004-05-12 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect |
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| WO2006046040A1 (en) | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds |
| US20060115824A1 (en) * | 2004-04-15 | 2006-06-01 | Institute For Environmental Health, Inc. | Trend analysis and statistical process control using multitargeted screening assays |
| US20060270673A1 (en) | 2003-04-24 | 2006-11-30 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2007042806A1 (en) | 2005-10-11 | 2007-04-19 | Ludwig Institute For Cancer Research | Pyrimidine derivatives for the treatment of cancer |
| US20080039459A1 (en) | 2006-04-26 | 2008-02-14 | Plramed Limited | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US20080076768A1 (en) | 2006-04-26 | 2008-03-27 | Piramed Limited | Pharmaceutical compounds |
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| WO2008073785A2 (en) | 2006-12-07 | 2008-06-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US7534584B2 (en) * | 2004-08-06 | 2009-05-19 | Institute For Environmental Health, Inc. | Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents |
| WO2009105712A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| WO2009111547A1 (en) | 2008-03-04 | 2009-09-11 | Wyeth | 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| WO2009109867A2 (en) | 2008-03-04 | 2009-09-11 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| WO2009111531A1 (en) | 2008-03-06 | 2009-09-11 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7589101B2 (en) | 2005-08-16 | 2009-09-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| US20090233950A1 (en) | 2006-03-02 | 2009-09-17 | Frederic Henri Jung | Quinazoline derivatives |
| WO2009112565A1 (en) | 2008-03-13 | 2009-09-17 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazoles |
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| US20090234132A1 (en) | 2006-05-23 | 2009-09-17 | Novartis Ag | 5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors |
| US20090233926A1 (en) | 2006-09-14 | 2009-09-17 | Astrazeneca | 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
| WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
| US20090239859A1 (en) | 2008-02-29 | 2009-09-24 | Chua Peter C | Protein kinase modulators |
| WO2009117482A1 (en) | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms |
| US20090239847A1 (en) | 2008-03-19 | 2009-09-24 | Ian Bruce | Organic compounds |
| US20090239936A1 (en) | 2006-05-15 | 2009-09-24 | Yoshikazu Sugimoto | Prophylactic and Therapeutic Agent for Cancer |
| US20090238828A1 (en) | 2004-08-14 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Combinations for the Treatment of Diseases involving Cell Proliferation |
| US7595330B2 (en) | 2005-09-06 | 2009-09-29 | Smithkline Beecham Corporation | Benzimidazole thiophene compounds |
| US7595320B2 (en) | 2005-03-04 | 2009-09-29 | Aventis Pharma S.A. | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof |
| US20090247538A1 (en) | 2004-10-25 | 2009-10-01 | Astex Therapeutics Limited | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors |
| WO2009120094A2 (en) | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| US20090247565A1 (en) | 2005-10-21 | 2009-10-01 | Jongwon Lim | Tyrosine Kinase Inhibitors |
| US20090247567A1 (en) | 2008-03-31 | 2009-10-01 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
| US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7598245B2 (en) | 2003-08-06 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| US7601724B2 (en) | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7601718B2 (en) | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
| US20090258852A1 (en) | 2005-07-08 | 2009-10-15 | Arrington Kenneth L | Inhibitors of Checkpoint Kinases |
| US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7605160B2 (en) | 2006-08-09 | 2009-10-20 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2009129259A2 (en) | 2008-04-16 | 2009-10-22 | Takeda Pharmaceutical Company Limited | Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor |
| WO2009129211A1 (en) | 2008-04-16 | 2009-10-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
| US20090263397A1 (en) | 2007-07-06 | 2009-10-22 | Buck Elizabeth A | Combination anti-cancer therapy |
| US7608622B2 (en) | 2004-09-24 | 2009-10-27 | Janssen Pharmaceutica Nv | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases |
| US20090270430A1 (en) | 2005-10-07 | 2009-10-29 | Exelixix, Inc. | Pyridopyrimidinone Inhibitors of Pl3Kalpha |
| US20090270621A1 (en) | 2003-08-14 | 2009-10-29 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US20090270445A1 (en) | 2006-01-18 | 2009-10-29 | Amgen Inc. | Thiazole compounds and methods of use |
-
2010
- 2010-10-19 WO PCT/US2010/002804 patent/WO2011049625A1/en not_active Ceased
Patent Citations (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| US3969287A (en) | 1972-12-08 | 1976-07-13 | Boehringer Mannheim Gmbh | Carrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding group and reacting the product with a carrier |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| US4247642A (en) | 1977-02-17 | 1981-01-27 | Sumitomo Chemical Company, Limited | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US4301144A (en) | 1979-07-11 | 1981-11-17 | Ajinomoto Company, Incorporated | Blood substitute containing modified hemoglobin |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4670417A (en) | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| WO1990005719A1 (en) | 1988-11-23 | 1990-05-31 | British Bio-Technology Limited | Hydroxamic acid based collagenase inhibitors |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1993021259A1 (en) | 1992-04-14 | 1993-10-28 | Cornell Research Foundation Inc. | Dendritic based macromolecules and method of production |
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
| EP0606046A1 (en) | 1993-01-06 | 1994-07-13 | Ciba-Geigy Ag | Arylsulfonamido-substituted hydroxamic acids |
| JPH08176070A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Didepside derivative and PI3 kinase inhibitor |
| JPH08175990A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | PI3 kinase inhibitor and method for producing the same |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| WO1996027583A1 (en) | 1995-03-08 | 1996-09-12 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| US5861510A (en) | 1995-04-20 | 1999-01-19 | Pfizer Inc | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors |
| WO1996033172A1 (en) | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
| WO1997015658A1 (en) | 1995-10-26 | 1997-05-01 | Ludwig Institute For Cancer Research | Wortmannin phosphoinositide 3-kinase interaction site |
| EP0780386A1 (en) | 1995-12-20 | 1997-06-25 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
| WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| WO1998007697A1 (en) | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| WO1998033768A1 (en) | 1997-02-03 | 1998-08-06 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| WO1998034915A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| WO1998034918A1 (en) | 1997-02-11 | 1998-08-13 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| WO1999002514A2 (en) | 1997-07-08 | 1999-01-21 | Bristol-Myers Squibb Company | Epothilone derivatives |
| WO1999029667A1 (en) | 1997-12-05 | 1999-06-17 | Pfizer Limited | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors |
| EP0931788A2 (en) | 1998-01-27 | 1999-07-28 | Pfizer Limited | Metalloprotease inhibitors |
| WO1999052910A1 (en) | 1998-04-10 | 1999-10-21 | Pfizer Products Inc. | Bicyclic hydroxamic acid derivatives |
| WO1999052889A1 (en) | 1998-04-10 | 1999-10-21 | Pfizer Products Inc. | (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
| JP2001247477A (en) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | Antitumor agent |
| WO2001081346A2 (en) | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US6800620B2 (en) | 2000-04-25 | 2004-10-05 | Icos | Inhibitors of human phosphatidylinositol 3-kinase delta |
| US6770641B2 (en) | 2000-04-27 | 2004-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| US7173029B2 (en) | 2000-04-27 | 2007-02-06 | Astellas Pharma Inc. | Fused heteroaryl derivatives |
| US6838457B2 (en) | 2000-04-27 | 2005-01-04 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| US6608056B1 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd | Fused heteroaryl derivatives |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| US6653320B2 (en) | 2000-04-27 | 2003-11-25 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives |
| US7037915B2 (en) | 2000-04-27 | 2006-05-02 | Astellas Pharma Inc. | Fused heteroaryl derivatives |
| US20040053946A1 (en) | 2001-01-16 | 2004-03-18 | Lackey Karen Elizabeth | Cancer treatment method |
| EP1417976A1 (en) | 2001-07-26 | 2004-05-12 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect |
| US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
| WO2003035618A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| WO2003034997A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| US20030158212A1 (en) | 2001-10-24 | 2003-08-21 | Teri Melese | Modulators of phosphoinositide 3-kinase |
| US20030149074A1 (en) | 2001-10-24 | 2003-08-07 | Teri Melese | Modulators of phosphoinositide 3-kinase |
| WO2003037886A2 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| WO2004007491A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives |
| WO2004006916A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7601724B2 (en) | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| US7601718B2 (en) | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20060270673A1 (en) | 2003-04-24 | 2006-11-30 | Merck & Co., Inc. | Inhibitors of akt activity |
| US7598245B2 (en) | 2003-08-06 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| US20090270621A1 (en) | 2003-08-14 | 2009-10-29 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| US20060115824A1 (en) * | 2004-04-15 | 2006-06-01 | Institute For Environmental Health, Inc. | Trend analysis and statistical process control using multitargeted screening assays |
| US20090258359A1 (en) * | 2004-08-06 | 2009-10-15 | Institute For Environmental Health | Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents |
| US7534584B2 (en) * | 2004-08-06 | 2009-05-19 | Institute For Environmental Health, Inc. | Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents |
| US20090238828A1 (en) | 2004-08-14 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Combinations for the Treatment of Diseases involving Cell Proliferation |
| US7608622B2 (en) | 2004-09-24 | 2009-10-27 | Janssen Pharmaceutica Nv | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases |
| US20090247538A1 (en) | 2004-10-25 | 2009-10-01 | Astex Therapeutics Limited | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors |
| US20080207611A1 (en) | 2004-10-25 | 2008-08-28 | Plramed Limited | Pharmaceutical compounds |
| WO2006046035A1 (en) | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds |
| WO2006046031A1 (en) | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds |
| WO2006046040A1 (en) | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds |
| US7595320B2 (en) | 2005-03-04 | 2009-09-29 | Aventis Pharma S.A. | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof |
| US20090258852A1 (en) | 2005-07-08 | 2009-10-15 | Arrington Kenneth L | Inhibitors of Checkpoint Kinases |
| US7589101B2 (en) | 2005-08-16 | 2009-09-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US7595330B2 (en) | 2005-09-06 | 2009-09-29 | Smithkline Beecham Corporation | Benzimidazole thiophene compounds |
| US20090270430A1 (en) | 2005-10-07 | 2009-10-29 | Exelixix, Inc. | Pyridopyrimidinone Inhibitors of Pl3Kalpha |
| WO2007042810A1 (en) | 2005-10-11 | 2007-04-19 | Ludwig Institute For Cancer Research | Pyrimidine derivatives for the treatment of cancer |
| WO2007042806A1 (en) | 2005-10-11 | 2007-04-19 | Ludwig Institute For Cancer Research | Pyrimidine derivatives for the treatment of cancer |
| US20090247565A1 (en) | 2005-10-21 | 2009-10-01 | Jongwon Lim | Tyrosine Kinase Inhibitors |
| US20090270445A1 (en) | 2006-01-18 | 2009-10-29 | Amgen Inc. | Thiazole compounds and methods of use |
| US20090233950A1 (en) | 2006-03-02 | 2009-09-17 | Frederic Henri Jung | Quinazoline derivatives |
| US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors |
| US20080039459A1 (en) | 2006-04-26 | 2008-02-14 | Plramed Limited | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US20080076768A1 (en) | 2006-04-26 | 2008-03-27 | Piramed Limited | Pharmaceutical compounds |
| US20090239936A1 (en) | 2006-05-15 | 2009-09-24 | Yoshikazu Sugimoto | Prophylactic and Therapeutic Agent for Cancer |
| US20090234132A1 (en) | 2006-05-23 | 2009-09-17 | Novartis Ag | 5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors |
| US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US7605160B2 (en) | 2006-08-09 | 2009-10-20 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US20090233926A1 (en) | 2006-09-14 | 2009-09-17 | Astrazeneca | 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008073785A2 (en) | 2006-12-07 | 2008-06-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
| US20090263397A1 (en) | 2007-07-06 | 2009-10-22 | Buck Elizabeth A | Combination anti-cancer therapy |
| WO2009105712A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| US20090239859A1 (en) | 2008-02-29 | 2009-09-24 | Chua Peter C | Protein kinase modulators |
| WO2009109867A2 (en) | 2008-03-04 | 2009-09-11 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| WO2009111547A1 (en) | 2008-03-04 | 2009-09-11 | Wyeth | 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| WO2009111531A1 (en) | 2008-03-06 | 2009-09-11 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2009112565A1 (en) | 2008-03-13 | 2009-09-17 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazoles |
| WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| US20090239847A1 (en) | 2008-03-19 | 2009-09-24 | Ian Bruce | Organic compounds |
| WO2009117482A1 (en) | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms |
| WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
| WO2009120094A2 (en) | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| US20090247567A1 (en) | 2008-03-31 | 2009-10-01 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
| WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
| WO2009129259A2 (en) | 2008-04-16 | 2009-10-22 | Takeda Pharmaceutical Company Limited | Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor |
| WO2009129211A1 (en) | 2008-04-16 | 2009-10-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
Non-Patent Citations (91)
| Title |
|---|
| "Basic and Clinical Pharmacology", 2003, MCGRAW HILL |
| "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS |
| "Goodman and Gilman's The Pharmacological Basis of Therapeutics", 1996, pages: 11 - 16 |
| "Handbook of Clinical Drug Data", 2002, MCGRAW-HILL |
| "Principles of Drug Action", 1990, CHURCHILL LIVINGSTON |
| "Remingtons Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS. |
| "The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL |
| ABID ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., vol. 24, 2004, pages 294 - 300 |
| AOUDJIT ET AL., J. IMMUNOL., vol. 161, 1998, pages 2333 - 2338 |
| B. MARKMAN, ANNALS OF ONCOLOGY ADVANCE ACCESS, August 2009 (2009-08-01) |
| BACKER JM., BIOCHEM J, vol. 410, 2008, pages 1 - 17 |
| BENNETT ET AL., J. PHARMACOL. EXP. THER., vol. 280, 1997, pages 988 - 1000 |
| BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 2008, pages 159 - 185 |
| BLOEMEN ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 153, 1996, pages 521 - 529 |
| BLUME- JENSEN P ET AL., NATURE, vol. 411, no. 6835, 2001, pages 355 - 365 |
| BOWES ET AL., EXP. NEUROL., vol. 119, 1993, pages 215 - 219 |
| BURGERING ET AL., NATURE, vol. 376, 1995, pages 599 - 602 |
| CARNERO A, CURR CANCER DRUG TARGETS, vol. 8, 2008, pages 187 - 98 |
| CHIOSIS ET AL., BIOORGANIC & MED. CHEM. LETT., vol. 11, 2001, pages 909 - 913 |
| CHOPP ET AL., STROKE, vol. 25, 1994, pages 869 - 875 |
| CLARK ET AL., NEUROSURG., vol. 75, 1991, pages 623 - 627 |
| COSIMI ET AL., J. IMMUNOL., vol. 144, 1990, pages 4604 - 4612 |
| COUSSENS; WERB, NATURE, vol. 420, 2002, pages 860 - 867 |
| DEMEESTER ET AL., TRANSPLANTATION, vol. 62, 1996, pages 1477 - 1485 |
| ENGELMAN JA, NAT REV GENET, vol. 7, 2006, pages 606 - 19 |
| EXPERT OPIN. INVESTIG. DRUGS, vol. 18, no. 9, 2009, pages 1265 - 12 77 |
| FISHMAN ET AL.: "Medicine", 1985, J.B. LIPPINCOTT CO. |
| FRASER ET AL., SCIENCE, vol. 251, 1991, pages 313 - 16 |
| FRUMAN ET AL., ANN REV BIOCHEM, vol. 67, 1998, pages 481 - 507 |
| GORCZYNSKI; WOJCIK, J. IMMUNOL., vol. 152, 1994, pages 2011 - 2019 |
| GROSS ET AL., SCIENCE, vol. 218, 1998, pages 703 - 706 |
| GUTE ET AL., MOL. CELL BIOCHEM., vol. 179, 1998, pages 169 - 187 |
| HALLAHAN ET AL., PROC. NATL. ACAD. SCI (USA), vol. 94, 1997, pages 6432 - 6437 |
| HALLORAN ET AL., ARTHRITIS RHEUM., vol. 39, 1996, pages 810 - 819 |
| HARARI ET AL., ONCOGENE, vol. 19, 2000, pages 6102 - 6114 |
| HARNING ET AL., TRANSPLANTATION, vol. 52, 1991, pages 842 - 845 |
| HARTMAN ET AL., CARDIOVASC. RES., vol. 30, 1995, pages 47 - 54 |
| HASAGAWA ET AL., INT. IMMUNOL., vol. 6, 1994, pages 831 - 838 |
| HE ET AL., OPTHALMOL. VIS. SCI., vol. 35, 1994, pages 3218 - 3225 |
| HERROLD ET AL., CELL IMMUNOL., vol. 157, 1994, pages 489 - 500 |
| HIGUCHI ET AL.: "Prodrugs as Novel Delivery Systems", ASCD SYMPOSIUM SERIES, vol. 14 |
| HORGAN ET AL., AM. J. PHYSIOL., vol. 261, 1991, pages H1578 - H1584 |
| ISOBE ET AL., SCIENCE, vol. 255, 1992, pages 1125 - 1127 |
| KAKIMOTO ET AL., CELL. IMMUNOL., vol. 142, 1992, pages 326 - 337 |
| KAUFFMANN-ZEH ET AL., NATURE, vol. 385, 1997, pages 544 - 548 |
| KAWASAKI ET AL., J. IMMUNOL., vol. 150, 1993, pages 1074 - 1083 |
| KNOERZER ET AL., TOXICOL. PATHOL., vol. 25, 1997, pages 13 - 19 |
| LEMMON ET AL., TRENDS CELL BIOL, vol. 7, 1997, pages 237 - 42 |
| MA ET AL., ONCOGENE, vol. 19, 2000, pages 2739 - 2744 |
| MARTINDALE: "The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS |
| MATTER A., DRUG DISC TECHNOL, vol. 6, 2001, pages 1005 - 1024 |
| MULLIGAN ET AL., J. IMMUNOL., vol. 154, 1995, pages 1350 - 1363 |
| MURPHY ET AL.: "Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery", 1997, PENGUIN BOOKS U.S.A., INC. |
| NAGASE ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 154, 1996, pages 504 - 510 |
| NAKAO ET AL., MUSCLE NERVE, vol. 18, 1995, pages 93 - 102 |
| NATHAN T., MOL CANCER THER., vol. 8, no. 1, January 2009 (2009-01-01) |
| NICHOLSON; ANDERSON, CELLULAR SIGNALLING, vol. H, 2002, pages 381 - 395 |
| OPPENHEIMER-MARKS ET AL., J. CLIN. INVEST., vol. 101, 1998, pages 1261 - 1272 |
| OSHIRO ET AL., STROKE, vol. 28, 1997, pages 2031 - 2038 |
| PAGES ET AL., NATURE, vol. 369, 1994, pages 327 - 29 |
| PANAYOTOU ET AL., TRENDS CELL BIOL, vol. 2, 1992, pages 358 - 60 |
| PANES ET AL., GASTROENTEROLOGY, vol. 108, 1995, pages 1761 - 1769 |
| PARKER ET AL., CURRENT BIOLOGY, vol. 5, 1995, pages 577 - 99 |
| PHILLIPS ET AL., CANCER, vol. 83, 1998, pages 41 |
| PHILP ET AL., CANCER RESEARCH, vol. 61, 2001, pages 7426 - 7429 |
| PIXU LIU, NATURE REVIEWS DRUG DISCOVERY, vol. 8, 2009, pages 627 - 644 |
| RAMEH ET AL., J. BIOL CHEM, vol. 274, 1999, pages 8347 - 8350 |
| REMINGTON'S PHARMACEUTICAL SCIENCES, pages 1435 - 1712 |
| ROMINA MARONE, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 2008, pages 159 - 185 |
| RUDD, IMMUNITY, vol. 4, 1996, pages 527 - 34 |
| SAMUELS ET AL., SCIENCE, vol. 304, 2004, pages 554 |
| SAWYER, EXPERT OPINION INVESTIG. DRUGS, vol. JJ., 2004, pages 1 - 19 |
| SCHIMMER ET AL., J. IMMUNOL., vol. 160, 1998, pages 1466 - 1477 |
| SHAYESTEH ET AL., NATURE GENETICS., vol. 21, 1999, pages 99 - 102 |
| SIMPSON; PARSONS, EXP. CELL RES., vol. 264, 2001, pages 29 - 41 |
| STERNMARK ET AL., J CELL SCI, vol. 112, 1999, pages 4175 - 83 |
| T. W. GREENE: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS |
| TALENTO ET AL., TRANSPLANTATION, vol. 55, 1993, pages 418 - 422 |
| TAMIYA ET AL., IMMUNOPHARMACOLOGY, vol. 29, 1995, pages 53 - 63 |
| TANAKA ET AL., J. IMMUNOL., vol. 151, 1993, pages 5088 - 5095 |
| VANHAESEBROECK B, TRENDS BIOCHEM SCI, vol. 30, 2005, pages 194 - 204 |
| VARA ET AL., CANCER TREATMENT REVIEWS, vol. 30, 2004, pages 193 - 204 |
| VIVANCO ET AL., NATURE REV. CANCER, vol. 2, 2002, pages 489 |
| VIVANCO; SAWYERS, NATURE REVIEWS CANCER, vol. 2, 2002, pages 489 - 501 |
| VLAHOS ET AL., J. BIOL. CHEM., vol. 269, no. 7, 1994, pages 5241 - 5248 |
| WALKER ET AL., MOL. CELL, vol. 6, 2000, pages 909 - 919 |
| WEGNER ET AL., LUNG, vol. 170, 1992, pages 267 - 279 |
| WEGNER ET AL., SCIENCE, vol. 247, 1990, pages 456 - 459 |
| WHITMAN ET AL., NATURE, vol. 332, 1988, pages 664 |
| YAO ET AL., SCIENCE, vol. 267, 1995, pages 2003 - 05 |
| ZENG ET AL., TRANSPLANTATION, vol. 58, 1994, pages 681 - 689 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Quevauviller et al. | Certified reference materials for the quality control of EDTA-and acetic acid-extractable contents of trace elements in sewage sludge amended soils (CRMs 483 and 484) | |
| Benoist et al. | Biasing in the galaxy distribution | |
| Bruins Slot et al. | Evaluating the performance of gluten ELISA test kits: The numbers do not tell the tale | |
| De Saeger | Determining mycotoxins and mycotoxigenic fungi in food and feed | |
| Schuller et al. | A review of sampling plans and collaboratively studied methods of analysis for aflatoxins | |
| US20120090410A1 (en) | Method for aflatoxin screening of products | |
| Tittlemier et al. | Sampling of cereals and cereal-based foods for the determination of ochratoxin A: an overview | |
| WO2011049625A1 (en) | Method for aflatoxin screening of products | |
| WO2002103329A3 (en) | Apparatus and method for determining the dispersibility of a product in particulate form | |
| Sfeir et al. | An evaluation of municipal solid waste composition bias sources | |
| Stroka et al. | Novel sampling methods for the analysis of mycotoxins and the combination with spectroscopic methods for the rapid evaluation of deoxynivalenol contamination | |
| Tittlemier et al. | By-products of grain cleaning: an opportunity for rapid sampling and screening of wheat for mycotoxins | |
| Maestroni et al. | Sampling strategies to control mycotoxins | |
| Coker | Design of sampling plans for determination of mycotoxins in foods and feeds | |
| US20130199287A1 (en) | Auto Micronaire | |
| Whitaker et al. | Performance of sampling plans to determine aflatoxin in farmers’ stock peanut lots by measuring aflatoxin in high-risk-grade components | |
| Haarer et al. | Early enrichment and restitution of the peripheral blood treg pool is associated with rejection-free stable immunosuppression after liver transplantation | |
| Daun et al. | How green is green? Sampling and perception in assessing green seeds and chlorophyll in canola | |
| Gu et al. | Preparation and Certification of High‐Grade Gold Ore Reference Materials (GAu 19‐22) | |
| Falconer et al. | Automated color sorting of hand-harvested Chardonnay | |
| Sezer et al. | Waste characterization at mixed municipal solid waste composting and recycling facility units | |
| Masoumi et al. | Design, construction and evaluation of an automatic apple grading system | |
| Park et al. | Performance of three pneumatic probe samplers and four analytical methods used to estimate aflatoxins in bulk cottonseed | |
| CN106950238A (en) | A kind of Fast nondestructive evaluation and the method for filtering out low cadmium rice or brown rice simultaneously | |
| US20070017854A1 (en) | Method and system for mitigating threats and hoaxes perpetrated through a mail system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10825332 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10825332 Country of ref document: EP Kind code of ref document: A1 |